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Abstract
Pulmonary hypertension (PH) has been reported with nearly all forms of the inherited as well as the
acquired hemolytic anemias. Recent research investigating the pathophysiology of PH in sickle cell
disease and thalassemia has helped elucidate the central role of hemolysis-mediated endothelial
dysfunction in the development of PH in these populations. Although the most appropriate treatment
of PH in patients with hemolytic anemia is not clearly defined, the associated significant increased risk
of death underscores the need for randomized clinical trials in this area.
Introduction and context
Pulmonary hypertension (PH) is a syndrome of
restricted blood flow through the pulmonary arterial
circulation associated with increased pulmonary vascular
resistance and elevated pulmonary artery pressures.
While there are case reports of this syndrome occurring
in most hemolytic anemias, including hereditary spher-
ocytosis, pyruvate kinase deficiency, unstable hemoglo-
bin variants, paroxysmal nocturnal hemoglobinuria, and
microangiopathic hemolytic anemias [1-6], data from
larger cohorts have been reported only in sickle cell
disease (SCD) and thalassemia and will be the focus of
this report. The gold standard for diagnosis of PH is
elevated mean pulmonary artery pressure (mPAP) of
≥25 mmHg measured during right heart catheterization.
Echocardiography can be used as a noninvasive method
to estimate pulmonary pressures by measuring the
tricuspid regurgitant jet velocity (TRV). A TRV of
≥2.5 m/s has been validated as a reliable predictor of
elevated pulmonary artery pressures in idiopathic PH [7]
and has also been shown to correlate well with mPAP
measured during catheterization in adult SCD patients
[8]. Recent research has helped define the link between
hemolysis and the development of pulmonary hyperten-
sion, establish the prevalence and risk factors for its
development and, perhaps most importantly, identify
PH as a significant marker for death.
Recent advances
Pathophysiology
While the initial mechanism of injury in various forms of
PH may vary, the end result is a range of endothelial
damage seen on histopathology, including hyperplasia,
proliferation, thrombosis in situ, and finally irreversible
plexiform arteriopathy [7]. The pathways that lead to this
injury as a result of hemolysis are multifactorial and
involve nitric oxide depletion and reduced bioavailabil-
ity, dysregulation of arginine metabolism, oxidative
stress, and a hypercoagulable state. Nitric oxide (NO),
synthesized from arginine by endothelial nitric oxide
synthase, plays a critical role in maintaining vascular
homeostasis. Not only does NO maintain vasodilation
by activating cGMP-dependent protein kinases, but it
also inhibits platelet aggregation and attachment, limits
ischemia-reperfusion injury and down-regulates adhe-
sion molecules such as vascular cell adhesion molecule,
selectins, and the potent vasoconstrictor endothelin-1
[9]. During hemolysis, breakdown of the erythrocyte
releases hemoglobin and the enzyme arginase into
circulation. Cell-free hemoglobin has been shown to be
a potent scavenger of NO, effectively preventing these
vasoprotective properties [10]. In addition, arginase
depletes the substrate for NO synthesis by conversion
of arginine to ornithine, compounding the state of
reduced NO bioavailability. The downstream products
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include proline and polyamines, metabolites known to
increase vascular smooth muscle proliferation and
collagen production and deposition, respectively [11].
Collectively, these changes result in vasoconstriction and
vascular remodeling of the pulmonary vascular endothe-
lium. The relationship between hemolysis, NO deple-
tion, arginine metabolism dysregulation, and PH has
been demonstrated in animal models as well as in vitro
and in vivo experiments over the past few years. Multiple
studies in adults as well as children with SCD have
identified a strong link between the intensity of
hemolysis and development of PH [8,12,13]. Mouse
models of SCD as well as alloimmune hemolytic anemia
with intravascular hemolysis have been shown to
develop PH [14]. Canine modes of intravascular
hemolysis also demonstrate induction of PH that is
partially reversed by administration of NO [15]. Reiter
et al. [10] showed that plasma from SCD patients
consumes NO and the inactivation of NO is directly
proportional to the hemolytic rate. Arginase activity has
also been shown to correlate with the hemolytic rate and
a low arginine to ornithine ratio reflecting the dysregula-
tion of arginine metabolism has been found in
thalassemia and SCD. In patients with SCD, this ratio
correlates significantly with PH [11].
The oxidative damage that occurs with chronic hemolysis
also likely contributes to the development of PH.
Reduced glutathione is a critical antioxidant and its
depletion has recently been shown to correlate with
hemolysis and was independently associated with PH in
SCD patients [16]. Finally, the hypercoagulable state
associated with SCD and thalassemia has been shown to
contribute to the development of PH through a series of
recent experiments. Villagra et al. [17] showed the
correlation between platelet activation, markers of
hemolysis, and severity of PH in SCD. Kuypers [18] has
demonstrated the procoagulant nature of the abnormal
erythrocyte membrane that occurs with oxidative
damage in hemolytic anemias. Setty et al. [19] has
reported increased tissue factor expression and thrombin
generation induced by free heme. Splenectomy contri-
butes to this hypercoagulable state and is a known risk
factor for PH in thalassemia [20]. Singer et al. [21] have
reported an association between PH and platelet activa-
tion, hypercoagulability, and splenectomy in patients
with thalassemia.
In summary, the development of PH due to hemolysis is
multifactorial and involves NO deficiency, dysregulated
arginine metabolism, oxidative stress, and hypercoagul-
ability. Although the chronology of the vascular injury
that leads to PH is not completely defined, there is likely
some initial vasoconstriction and proliferative vasculo-
pathy that progresses to irreversible luminal narrowing
with vascular remodeling over time (Figure 1).
Prevalence
Multiple prospective screening studies have found
roughly a third of adult patients with SCD have PH as
Figure 1. Progression of pulmonary hypertension in sickle cell
disease and thalassemia
In this hypothetical model, impaired nitric oxide (NO) bioavailability that
results from chronic hemolysis and oxidative stress triggers chronic
pulmonary vasoconstriction, mildly elevating pulmonary vascular resistance
and pulmonary artery pressures. Excess arginase liberated from the
erythrocyte during hemolysis consumes arginine, the obligate substrate for
NO production, and creates a shift towards ornithine production that
contributes to collagen deposition and vascular smooth muscle prolifera-
tion. Overabundant thrombin generation contributes to a chronic
hypercoagulable state, increases arginase activity, and stimulates polyamine
synthesis in vascular smooth muscle cells. As this becomes more long-
standing, vascular smooth muscle hyperplasia begins to create a relatively
fixed lesion, compounded in later stages by irregular, activated endothelium
with expression of adhesion molecules. In situ thrombosis further occludes
the vessel lumen, and results in plexogenic changes, further accelerating the
progression of the pulmonary artery hypertension (PAH). Figure and
caption reproduced with permission from [13]. Copyright © 2007 Informa
Healthcare.
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have severe PH (TRV of >3 m/s) [8,22-24]. Most reports
of PH in pediatric SCD patients have also found a
prevalence of 30%, although most of these are retro-
spective and therefore associated with some selection
bias due to screening of symptomatic patients [25-27].
A recent study of children with SCD prospectively
screened with echocardiography reported PH in 11% of
290 patients [28].
Studies of PH in thalassemia patients report less
consistent results with a prevalence range of 10-75%
depending on age, transfusion regimen, and degree of
left ventricular dysfunction. Thalassemia major (TM)
patients have a more clinically severe anemia and are
typically transfusion dependent very early in life whereas
thalassemia intermedia (TI) patients have a later onset of
symptoms and may be less frequently transfused.
Transfusions appear to have a preventative effect as PH
is more frequently reported with TI compared to
regularly transfused TM patients. Aessopos et al. [29]
compared 131 transfused TM and 74 non-transfused TI
patients and found PH in 23% of TI patients and no PH
in the TM cohort. Singer et al. [21] reported PH in 10 of
18 transfused TM and 7 of 7 TI patients. Others have
found PH in 44% of 36 [30] and 9.8% of 368 [31]
regularly transfused TM patients.
Amino-terminal pro-brain natriuretic peptide
High levels of brain natriuretic peptide (BNP) reflect
cardiac volume and pressure afterload as this hormone is
released in response to cardiomyocyte stretching. The
proBNP hormone is cleaved into the biologically active
BNP and an easily measurable inactive amino-terminal
proBNP. The amino-terminal proBNP level has been
shown to correlate with severity of pulmonary artery
pressure elevation and right ventricular dysfunction in
primary PH [7]. It has more recently been validated as a
biomarker for PH in SCD. Machado et al. [24] found that
amino-terminal proBNP levels were higher in SCD
patients with PH and correlated directly with TRV
(R = 0.5, P < 0.001). A level of 160 pg/ml or greater
had 78% positive predictive value for the diagnosis of PH
in this cohort. Importantly, they also found this level was
an independent predictor of mortality (relative risk for
death 5.1; 95% confidence interval 2.1-12.5; P < 0.001).
Risk of mortality
Heart failure is the most common cause of death in
thalassemia [32]. While this is commonly due to left
ventricular dysfunction resulting from transfusion-
induced iron overload, right heart failure is now
increasingly recognized [33]. Long-term longitudinal
studies of thalassemia patients are needed to further
delineate the contribution of PH to mortality in this
population.
Gladwin et al. [8] identified PH as a significant risk factor
for death in adults with SCD. In a cohort of 195 patients,
the rate ratio for death was 10.1 for those with TRV >2.5
m/s at a mean follow up of 18 months (Figure 2). This
significantly increased risk of death has been validated in
multiple other studies [22-24]. In a recent report of 88
children, all 18 patients with PH were alive at a mean
follow-up period of 3 years [34], suggesting there may be
some progressive damage over time that ultimately leads
to death in adulthood. It is important to note that this
increased mortality is seen despite the fact that the
mPAPs in hemolytic anemias are much lower than those
reported with idiopathic PH. It remains unclear if PH is
the direct cause of death or simply a marker of severe
vasculopathy in SCD. PH has been reported as a frequent
finding in autopsies of SCD patients with sudden death
[35] and vaso-occlusive pain crisis is known to com-
monly precede sudden death in these patients. Recent
work by Machado et al. [36] may shed light on the
pathophysiology of sudden death with the finding that,
during crisis, there is worsening of hemolysis as
measured by hemoglobin and lactate dehydrogenase
and also worsening of PH as measured by TRV. They
have speculated that acute worsening of PH during crisis
in patients who are already at the limits of cardio-
pulmonary compensation could potentially result in
either dysrhythmia or acute right ventricular failure.
More research is needed to further investigate these
results and clarify the cause and effect relationship of PH
and death in patients with hemolytic anemia.
Implications for clinical practice
Patients with hemolytic anemia and PH may be
asymptomatic or only mildly symptomatic. Even if
dyspnea on exertion or other symptoms develop, these
may be misinterpreted as either deconditioning or
simply due to chronic anemia. Therefore, clinicians
must maintain an index of suspicion and screen patients
with echocardiography. There are ongoing clinical trials
evaluating the most appropriate treatment strategies for
hemolysis-associated PH, although definitive treatment
guidelines have not been fully established. The findings
that regular transfusions may prevent or slow the
progression of PH in thalassemia [37,38] suggest a trial
of aggressive transfusion therapy is appropriate for these
patients. The known association of PH with hypercoa-
gulability, especially after splenectomy, in thalassemia
suggests preventative anticoagulation is warranted,
although there are no data to clarify if antiplatelet or
antithrombotic agents are more beneficial. Because of
the high prevalence of PH after splenectomy in TI, the
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For SCD-associated PH, most hematologists would
maximize sickle cell therapy with hydroxyurea or chronic
transfusions. It should be noted, however, that multiple
studies did not find an association with hydroxyurea use
and decreased TRV [8,24,40,41]. It is known that
hydroxyurea decreases hemolysis and induces NO in
endothelial cells [42] as well as improves clinical
symptoms with less reported pain and fewer hospitaliza-
tions [43,44]. Treatment with hydroxyurea may therefore
helppreventtheacuteepisodesthatexacerbatePHandare
potentiallyassociatedwithsuddendeath inthesepatients.
No prospective trials have evaluated the efficacy of
transfusion therapy to decrease PH, although chronic
transfusions are known to lower plasma free hemoglobin
[45] and there are a few case reports of improvement of
TRV with transfusion therapy [13]. One retrospective
evaluation of 55 nontransfused and 20 transfused
pediatric SCD patients found significantly lower TRV in
the transfused population [46].
Therapies specifically targeted at PH pathology include
vasodilatory agents, such as phosphodiesterase-5 inhibi-
tors and prostanoids, as well as endothelin receptor
antagonists and arginine supplementation. In a pilot
study of 12 SCD patients with PH, sildenafil showed a
Figure 2. Kaplan-Meier survival curves according to the tricuspid regurgitant jet velocity
The survival rate was significantly higher among patients with a tricuspid regurgitant jet velocity of <2.5 m/s (indicating normal pulmonary artery pressure)
than among those with a tricuspid regurgitant jet velocity of at least 2.5 m/s (P < 0.001). Because patients were enrolled over a 20-month period, the
first patients enrolled were followed for the entire time. Thus, the number of patients at risk at the time of each death is shown for both groups.
(Figure and caption reproduced with permission from [8]. Copyright © 2004 Massachusetts Medical Society. All rights reserved.
Page 4 of 6
(page number not for citation purposes)
f1000 Medicine Reports 2010, 2:10 http://f1000.com/reports/m/2/10decrease in TRV and pulmonary artery pressures as well
as functional improvement [47]. However, a large multi-
center trial treating PH with sildenafil was prematurely
closed as there was no functional improvement and
increased vaso-occlusive pain was reported in the
treatment group. Therefore, the role of sildenafil therapy
is still unclear. Treatment with arginine supplementation
was also shown to decrease pulmonary artery pressures
in ten SCD patients [48]; however, the number of pills
and dosing schedule required for an effect limit the use
of arginine in clinical practice. A recent study of 14 SCD
patients treated with the endothelin receptor antagonist
bosentan showed promising results with improved TRV
and mPAP [49].
Pulmonary hypertension is now an increasingly recog-
nized complication of hemolysis and is associated with
mortality in patients with hemolytic anemia. It remains
to be seen if PH directly results in death or simply
provides a window into the severity of vasculopathy for
patients with SCD. Ongoing research aims to define the
most effective treatment strategies for these patients and
enrolment in clinical trials is therefore of paramount
importance.
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